MEGA GENOMICS (06667) has released its interim financial results for the six-month period ended June 30, 2025. During the reporting period, the company achieved an operating revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2%. The net profit attributable to the company was RMB 27.3 million, which declined by 26.3% compared to the same period last year.

The decline in both operating revenue and net profit was primarily due to the company's strategic adjustment of its sales approach, leading to a temporary reduction in revenue. Concurrently, fixed costs such as labor, rent, and depreciation remained relatively stable, contributing to the decrease in net profit. As of June 30, 2025, the company has established collaborations with healthcare institutions in more than 340 cities across China.

Its extensive sales and marketing network enables the provision of genetic testing services to a significant portion of the Chinese population. Furthermore, the company has partnered with numerous e-commerce and online healthcare platforms to expand and enhance its sales and marketing network.